A Phase 2 interventional study of Topical application of 20% menthol solution in MCT oil. and Topical Placebo Oil rolled onto the cheek. in Healthy and Dry Eyes, sponsored by Reinhold Vieth. Enrolling by invitation at 1 site in Canada. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-16.
Sponsored by Reinhold Vieth · Phase 2, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies in Dry Eye Syndromes with a site in Canada — 5 open to participants now, 5 under way, 1 of them phase 3. Dry Eye Syndromes · Canada.
Among the 45 studies in Dry Eye Syndromes with a site in Canada, this one is the 28th largest by planned enrollment of the 37 interventional ones that give a count, is the only one that started in 2025, is one of 4 in phase 2, and was the 43rd registered.
1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.
Browse Dry Eye Syndromes studies →5 of the 45 studies in Dry Eye Syndromes with a site in Canada are open now. Recruiting first, the newest first:
Pleryon Therapeutics (Hangzhou) Limited · Sites in Canada
Ages 18+
Université de Sherbrooke · Sites in Canada
Ages 18+
Centre hospitalier de l'Université de Montréal (CHUM) · Sites in Canada
Ages 18+ · Healthy volunteers
Uptown Eye Specialists · Sites in Canada
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 117 Dry Eye Syndromes studies recruiting now, 74 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 60 across 1,132 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 48 across the 37 interventional studies, 55 across the 8 observational. Of the 37 that completed or were terminated, 18 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 45 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Reinhold Vieth as lead sponsor.
Reinhold Vieth has 1 study filed under Dry Eye Syndromes — fewer than ten, so there is no comparison to draw.
1 of the studies in Dry Eye Syndromes with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07593404Pleryon Therapeutics (Hangzhou) LimitedEvaluation of a Novel Ocular Lubricating Eye Drop | 2026-11 |
Add it to your calendar (.ics) → With an account.
Among the 45 studies in Dry Eye Syndromes with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Tears are the natural way to keep eyes moist, and tears are important for good vision and healthy eyes. Eyes without enought tears get dry and sore.
The natural and normal way to stimulate secretion of tears is by turning on cold sensors that are located on the cornea of the eye. Tear are normally released across the eyeball in a finely balanced system that balances out that natural evaporation. But sometimes there is not enough tear secretion to balance out the evaporation of tears and eyes can get sore.
The aim here is to test whether menthol in its vapor form may possibly turn on those cold sensors and thus cause secretion of tears. Use of menthol vapors may be like having a switch to release more tears.
The aim of this clinical trial is to test the hypothesis that a menthol solution applied onto a cheek will release enough menthol vapor into the air flowing up over the eye's cornea to stimulate cold sensors enough to make a tear flow from the eye.
If the hypothesis that menthol safely stimulates tear secretion in healthy people proves to be correct, then this clinical trial may inspire more new research into the use of menthol as an alternative to the use of eye drops for some people.
This is a proof-of-principle clinical trial. It is a double-blind, placebo-controlled, randomized clinical trial. Participants are not being seen by a physician for eye disease, and there is a 50% probability that a participant will receive active treatment, or 50% probability that they will just receive the carrier oil with nothing in it (placebo).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Excluded if "Yes" to any of the questions below.
Menthol solution rolled onto the cheek below rim of a pair of glasses
Drug: Topical application of 20% menthol solution in MCT oil.
Oil vehicle only rolled onto the cheek below rim of a pair of glasses
Drug: Topical Placebo Oil rolled onto the cheek.
To facilitate reproducible and correct application of the solution, the subject wears glasses while the product is applied. The solution is rolled onto one cheek by rolling it to an area of about 2cm X 2cm at the cheekbone, underneath the bottom rim of the glasses worn. This method delivers about 12 mg solution, i.e. 2.4 mg menthol to one cheek. Or this method delviers 12 mg of placebo oil. The subject then sits in still air for 5 minutes, at which point tissue is wiped across the skin below the bottom eyelashes to permit the weighing of secreted tear.
To facilitate reproducible and correct application of the Placebo oil, the subject wears glasses while the product is applied. The Placebo oil is rolled onto one cheek by rolling it to an area of about 2cm X 2cm at the cheekbone, underneath the bottom rim of the glasses worn. This method delivers zero active agent. The subject then sits in still air for 5 minutes, at which point tissue is wiped across the skin below the bottom eyelashes to permit the weighing of secreted tear.
Objective measure of tear stimulation Yes or No
The outcome is the binary yes/no observation of active tear secretion that overflows to the skin below the bottom eyelashes. Subject sits in still air while wearing glasses to ensure correct positioning of the topical application. The solution of menthol or placebo is dispensed from a roller-ball bottle to the right eye only, onto an area about 2cm x 2 cm just below the bottom rim of the glasses; that is, inferior to the pupil, and in line with the bottom of the nose. Within 5 minutes of sitting in still air, If moisture is evident below the bottom eyelashes, glasses are removed and tissue is dabbed, or wiped under bottom eyelash to take up the tear. If that wipe increases the weight of the tissue by at least 6 milligrams, then a "Yes" response is recorded. If after 5 minutes a wipe of tissue across the bottom eyelashes of the right eye does not increase the weight of tissue by at least 6 milligrams, a "No" is recorded to indicate that there was no increase in tear secretion.
Time frame: Participant is observed for 5 minutes after application, to record tear-weight data, and the related questions that are asked are completed within 10 minutes after applicaiton.
Weight of tear
The actual measured weight of the tear(s) collected onto the tissue, from below the right eye.
Time frame: Measured at 5 minutes after dose application.
Was there a subjective difference between left and right eyes in terms of sense if moisture
Response to the question: " Which eye feels more moist? Left eye more moist or No difference (both same) or ….Right eye more moist"
Time frame: 5 to 10 minutes after application
Weight of nasal secretion blown into tissue.
The purpose is to test whether there is evidence of shared innervation of TRPM8 receptors (the menthol-responsive sensors for cold) in cornea and nasal subepithelium. The particpant holds closed the left nostril, while blowing into a tissue from the right nostril. The increase in weight of tissue is measured.
Time frame: Within 10 minutes of applying the dose.
Weight of nasal secretion
Subject blows their nose into a tissue, and the increase in tissue weight is recorded.
Time frame: 5 to 10 minutes after application
Discomfortable feeling at the treated eye.
At your right eye, was there anything uncomfortable feeling? Nothing mild moderate severe (choose one)
Time frame: 10 minutes
Degree of cooling or pain at the skin where the dose was applied.
At the skin of the cheek, where it was rolled on, did you feel (choose one) COOLING OR NOTHING OR PAIN If cooling or pain, how strong was the feeling? (choose one) Nothing mild moderate severe
Time frame: 10 minutes
Did the procedure increase sense of runny nose?
Did you feel a runny nose, or nasal secretion during the 5 minutes of waiting? No or Yes And if Yes, at which nostril? Left or Right or Both nostrils
Time frame: 10 minutes
Plan to share: Yes — A spreadsheet of anonymized IPD collected throughout the trial may be made upon inquiry with the corresponding author of any peer-reviewed publication ensuing from this work.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: 1 month after final publication
Access criteria: The senior author of any ensuing publication will correspond with suitably qualified investigators, to discuss the type and form of data made available.
No publications or documents are linked to this record.
Started Aug 2025 (actual). Primary completion is estimated for Nov 2025, 2 months after the start.
Of 75 industry-sponsored phase 2 interventional studies under Dry Eye Syndromes, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 11. This study's planned 2 months is below that.
Counting every sponsor, half of 91 studies reached it within 7 months; a quarter within 5 and three quarters within 12.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.